cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccrl0lx
title: CCDC 702509: Experimental Crystal Structure Determination

description: Related Article: Fang Chen, Heng-Yun Ye|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|o1757|doi:10.1107/S160053680802552X
DOI: 10.5517/ccrkzw4
title: CCDC 702487: Experimental Crystal Structure Determination

description: Related Article: J.M.Chitanda, J.W.Quail, S.R.Foley|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|o1728|doi:10.1107/S1600536808024811
DOI: 10.5517/ccprvt2
title: CCDC 648545: Experimental Crystal Structure Determination

description: Related Article: Jinglin Wang, Bin Liu, Binsheng Yang|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1210|doi:10.1107/S1600536808027438
DOI: 10.5517/ccrkw27
title: CCDC 702369: Experimental Crystal Structure Determination

description: Related Article: M.Hitosugi-Levesque, J.M.Tanski|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1107|doi:10.1107/S1600536808023945
DOI: 10.5517/ccrkw38
title: CCDC 702370: Experimental Crystal Structure Determination

description: Related Article: Jun-Hua Li, Jing-Jing Nie, Duan-Jun Xu|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1108|doi:10.1107/S1600536808024215
DOI: 10.5517/ccrkw49
title: CCDC 702371: Experimental Crystal Structure Determination

description: Related Article: H.Yuge, N.Arakawa, S.Wada, T.K.Miyamoto|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1110|doi:10.1107/S1600536808023374
DOI: 10.5517/ccrkw5b
title: CCDC 702372: Experimental Crystal Structure Determination

description: Related Article: Chuan-Mei Tang, Guo-Hua Deng|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1111|doi:10.1107/S1600536808024252
DOI: 10.5517/ccrkw6c
title: CCDC 702373: Experimental Crystal Structure Determination

description: Related Article: Yan-Yan Sun, Ya-Wen Zhang, Gong Zhang, Lin Cheng|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1113|doi:10.1107/S1600536808023994
DOI: 10.5517/ccrkw7d
title: CCDC 702374: Experimental Crystal Structure Determination

description: Related Article: Zhong Zhang, Li-Zhen Wu, Zhi-Rong Geng, Zhi-Lin Wang|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1114|doi:10.1107/S1600536808024422
DOI: 10.5517/ccrkw8f
title: CCDC 702375: Experimental Crystal Structure Determination

description: Related Article: Hoong-Kun Fun, R.Kia|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1116|doi:10.1107/S1600536808024306
DOI: 10.5517/ccrkw9g
title: CCDC 702376: Experimental Crystal Structure Determination

description: Related Article: Qiu-sheng Wang, Jie Ouyang|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1118|doi:10.1107/S1600536808024379
DOI: 10.5517/ccrkwbh
title: CCDC 702377: Experimental Crystal Structure Determination

description: Related Article: Yuan Yang, Qi Li, S.W.Ng|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1119|doi:10.1107/S1600536808024331
DOI: 10.5517/ccrkwdk
title: CCDC 702379: Experimental Crystal Structure Determination

description: Related Article: M.Zeller, B.L.Westcott, K.M.Kopp-Vaughn, A.D.Hunter|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1121|doi:10.1107/S1600536808024197
DOI: 10.5517/ccrkwfl
title: CCDC 702380: Experimental Crystal Structure Determination

description: Related Article: B.L.Westcott, K.M.Kopp-Vaughn, L.M.Daniels, M.Zeller|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1122|doi:10.1107/S1600536808024203
DOI: 10.5517/ccrkwgm
title: CCDC 702381: Experimental Crystal Structure Determination

description: Related Article: M.Diallo, F.B.Tamboura, M.Gaye, A.H.Barry, Y.Bah|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1124|doi:10.1107/S1600536808024550
DOI: 10.5517/ccrkwhn
title: CCDC 702382: Experimental Crystal Structure Determination

description: Related Article: Xin-Sheng Li, Juan Mo, Su-Mei Zhang, Li Yuan, Jian-Hua Liu|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1126|doi:10.1107/S1600536808024537
DOI: 10.5517/ccrkwjp
title: CCDC 702383: Experimental Crystal Structure Determination

description: Related Article: Xin-Sheng Li, Juan Mo, Li Yuan, Jian-Hua Liu, Su-Mei Zhang|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1128|doi:10.1107/S1600536808024549
DOI: 10.5517/ccrkwkq
title: CCDC 702384: Experimental Crystal Structure Determination

description: Related Article: C.C.McLauchlan, A.E.Anderson|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1129|doi:10.1107/S1600536808024458
DOI: 10.5517/ccrkwlr
title: CCDC 702385: Experimental Crystal Structure Determination

description: Related Article: Shi Guo Zhang, Chao Hou|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1131|doi:10.1107/S1600536808024495
DOI: 10.5517/ccrkwms
title: CCDC 702386: Experimental Crystal Structure Determination

description: Related Article: Xin Jian Yao, Ya Wen Xuan, Wen Wu|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1132|doi:10.1107/S1600536808024793
DOI: 10.5517/ccqhl70
title: CCDC 670382: Experimental Crystal Structure Determination

description: Related Article: Wen-Kui Dong, Xiao Chen, Xue-Ni He, Xiao-Lu Tang, Zhong-Wu Lv|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1133|doi:10.1107/S1600536808024707
DOI: 10.5517/ccrkwnt
title: CCDC 702387: Experimental Crystal Structure Determination

description: Related Article: D.Kazhdan, Yung-Jin Hu, A.Kokai, Z.Levi, S.Rozenel|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1134|doi:10.1107/S1600536808024677
DOI: 10.5517/ccrkwpv
title: CCDC 702388: Experimental Crystal Structure Determination

description: Related Article: K.S.Luna-Ramirez, S.Bernes, L.Gasque|2008|Acta Crystallogr.,Sect.E:Struct.Rep.Online|64|m1135|doi:10.1107/S1600536808023969
DOI: 10.6084/m9.figshare.13633664
title: MR_Iron_T2D_Supplemental

description: Supplemental material
DOI: 10.6084/m9.figshare.13633664.v3
title: MR_Iron_T2D_Supplemental

description: Supplemental material
DOI: 10.6084/m9.figshare.13633664.v2
title: MR_Iron_T2D_Supplemental

description: Supplemental material
DOI: 10.6084/m9.figshare.12850514
title: Contributing factors to the plasma albumin level at diagnosis of hematological malignancy

description: Many factors contribute to the plasma albumin (PA) level. We aimed to quantify different factors’ relative contribution to the PA level when diagnosing hematological malignancy (HM). The study was a population-based registry study including patients with HM in a Danish region. We applied multivariate linear regression analyses with C-reactive protein (CRP), WHO performance score (WHO-PS), age, sex, comorbidity, and HM type as exposures and the PA level on the day of the HM diagnosis (DX) as the outcome. The relative contribution of each exposure was determined as a percentage of the models’ coefficient of determination (R<sup>2</sup>). In total, 2528 patients with HM had PA measured on DX. In the model comprising all exposures, CRP contributed with 65.8% to the R<sup>2</sup> of 0.389 whereas 3 variables (CRP, WHO-PS, HM type) together contributed with 96.1%. When CRP was excluded from the model, R<sup>2</sup> declined to 0.215 and the WHO-PS contributed with 96%. Other models, including separate analyses for each HM type, corroborated these results, except in myeloma patients where WHO-PS contributed with 61.1% to the R<sup>2</sup> of 0.234. The inflammation biomarker CRP was the main predictor of the PA level on DX. The WHO-PS also contributed to the PA level on DX whereas the remaining factors (HM type, age, sex, and comorbidity) were of much less importance.
DOI: 10.6084/m9.figshare.12850514.v1
title: Contributing factors to the plasma albumin level at diagnosis of hematological malignancy

description: Many factors contribute to the plasma albumin (PA) level. We aimed to quantify different factors’ relative contribution to the PA level when diagnosing hematological malignancy (HM). The study was a population-based registry study including patients with HM in a Danish region. We applied multivariate linear regression analyses with C-reactive protein (CRP), WHO performance score (WHO-PS), age, sex, comorbidity, and HM type as exposures and the PA level on the day of the HM diagnosis (DX) as the outcome. The relative contribution of each exposure was determined as a percentage of the models’ coefficient of determination (R<sup>2</sup>). In total, 2528 patients with HM had PA measured on DX. In the model comprising all exposures, CRP contributed with 65.8% to the R<sup>2</sup> of 0.389 whereas 3 variables (CRP, WHO-PS, HM type) together contributed with 96.1%. When CRP was excluded from the model, R<sup>2</sup> declined to 0.215 and the WHO-PS contributed with 96%. Other models, including separate analyses for each HM type, corroborated these results, except in myeloma patients where WHO-PS contributed with 61.1% to the R<sup>2</sup> of 0.234. The inflammation biomarker CRP was the main predictor of the PA level on DX. The WHO-PS also contributed to the PA level on DX whereas the remaining factors (HM type, age, sex, and comorbidity) were of much less importance.
DOI: 10.6084/m9.figshare.12850520.v1
title: Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff

description: To evaluate the association between biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) use and quality of life (QoL) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We evaluated adult patients prescribed biological DMARDs whose quality of life was evaluated at six and 12 months. The EuroQol 5 dimensions (EQ-5D) was used with the Brazilian tariff. Patients receiving bDMARDs had significant improvements in quality of life after 6 and 12 months (p 0.05). At the end of one year, 62.6% of the participants presented significant clinical improvement in QoL. According to a sensitivity analysis, QoL results in the complete case analysis and in the multiple imputation model yielded similar conclusions. Patients with two or more comorbidities and worse QoL and disability status on baseline presented worse QoL at 12 months when compared to those with better disability status on baseline. Baseline clinical disease measured by activity indexes (BASDAI and CDAI) did not influence QoL after 12 months of bDMARD treatment. Pain and malaise were the EQ-5D domain that most influenced quality of life. Patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis displayed significantly better QoL levels following treatment with DMARDs.
DOI: 10.6084/m9.figshare.11866371.v1
title: Evaluation of obstetric outcomes and prognostic significance of graft function in kidney transplant recipient pregnancies

description: To evaluate obstetric and kidney outcomes in pregnancies with kidney transplantation. We retrospectively reviewed 32 singleton pregnancies in kidney transplant recipients. Obstetric outcomes were explored according to the estimated glomerular filtration rates (eGFR) of patients. The incidences of fetal growth restriction, preeclampsia were 18.8% and 34.4%, respectively. There was a significant negative correlation between first-trimester eGFR and perinatal mortality (r = −0.546, p = .0.001) and composite adverse obstetric outcome (r = −0.415, p = .0.018). The degree of transplanted kidney function impairment at the beginning of pregnancy is the major determinant of pregnancy outcome.
DOI: 10.6084/m9.figshare.12850520
title: Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff

description: To evaluate the association between biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) use and quality of life (QoL) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We evaluated adult patients prescribed biological DMARDs whose quality of life was evaluated at six and 12 months. The EuroQol 5 dimensions (EQ-5D) was used with the Brazilian tariff. Patients receiving bDMARDs had significant improvements in quality of life after 6 and 12 months (p 0.05). At the end of one year, 62.6% of the participants presented significant clinical improvement in QoL. According to a sensitivity analysis, QoL results in the complete case analysis and in the multiple imputation model yielded similar conclusions. Patients with two or more comorbidities and worse QoL and disability status on baseline presented worse QoL at 12 months when compared to those with better disability status on baseline. Baseline clinical disease measured by activity indexes (BASDAI and CDAI) did not influence QoL after 12 months of bDMARD treatment. Pain and malaise were the EQ-5D domain that most influenced quality of life. Patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis displayed significantly better QoL levels following treatment with DMARDs.
DOI: 10.6084/m9.figshare.11866371
title: Evaluation of obstetric outcomes and prognostic significance of graft function in kidney transplant recipient pregnancies

description: To evaluate obstetric and kidney outcomes in pregnancies with kidney transplantation. We retrospectively reviewed 32 singleton pregnancies in kidney transplant recipients. Obstetric outcomes were explored according to the estimated glomerular filtration rates (eGFR) of patients. The incidences of fetal growth restriction, preeclampsia were 18.8% and 34.4%, respectively. There was a significant negative correlation between first-trimester eGFR and perinatal mortality (r = −0.546, p = .0.001) and composite adverse obstetric outcome (r = −0.415, p = .0.018). The degree of transplanted kidney function impairment at the beginning of pregnancy is the major determinant of pregnancy outcome.
DOI: 10.6084/m9.figshare.12850505
title: Simultaneous Characterization of Deletional and Nondeletional Globin Gene Mutations by Multiplex Real-Time-Polymerase Chain Reaction and High-Resolution Melting Curve Analysis

description: Both deletional and nondeletional globin gene mutations are common in Southeast Asians. Normally, deletional gene mutations are characterized separately from nondeletional gene mutations. Therefore, we developed a new approach of multiplex real-time polymerase chain reaction (qPCR) followed by high-resolution melting (HRM) analysis without a fluorescently-labeled probe for the simultaneous detection of deletional and nondeletional gene mutations in a single tube. Three sets of primer pairs were used to establish the qPCR-HRM method that was used to genotype more than 20 different globin genotypes. Twenty known genotypes were used to optimize the qPCR and HRM conditions. Eight genotypes were used to determine the reproducibility of the method. A total of 351 blinded known DNA samples were used for the validation study in three separate reactions and revealed 16 distinct patterns of fragments and/or HRM. The melting temperatures (Tm) of the 3.5 kb, – –<sup>THAI</sup>, <i>HBB</i>-FR2 (exon 1 of the <i>HBB</i> gene), – –<sup>SEA</sup> (Southeast Asian), α2 and 3'-ψζ1 fragments were 79.44, 81.01, 86.47, 87.89, 90.54 and 94.15 °C, respectively. The HRM analysis was performed with the <i>HBB</i>-FR2 fragment to differentiate several alleles. We report a rapid and high-throughput technique that showed 100.0% concordance and low variability for each run. Our developed technique is one of the alternative techniques recommended for screening samples with both deletional and nondeletional globin gene mutations.
DOI: 10.6084/m9.figshare.12850505.v1
title: Simultaneous Characterization of Deletional and Nondeletional Globin Gene Mutations by Multiplex Real-Time-Polymerase Chain Reaction and High-Resolution Melting Curve Analysis

description: Both deletional and nondeletional globin gene mutations are common in Southeast Asians. Normally, deletional gene mutations are characterized separately from nondeletional gene mutations. Therefore, we developed a new approach of multiplex real-time polymerase chain reaction (qPCR) followed by high-resolution melting (HRM) analysis without a fluorescently-labeled probe for the simultaneous detection of deletional and nondeletional gene mutations in a single tube. Three sets of primer pairs were used to establish the qPCR-HRM method that was used to genotype more than 20 different globin genotypes. Twenty known genotypes were used to optimize the qPCR and HRM conditions. Eight genotypes were used to determine the reproducibility of the method. A total of 351 blinded known DNA samples were used for the validation study in three separate reactions and revealed 16 distinct patterns of fragments and/or HRM. The melting temperatures (Tm) of the 3.5 kb, – –<sup>THAI</sup>, <i>HBB</i>-FR2 (exon 1 of the <i>HBB</i> gene), – –<sup>SEA</sup> (Southeast Asian), α2 and 3'-ψζ1 fragments were 79.44, 81.01, 86.47, 87.89, 90.54 and 94.15 °C, respectively. The HRM analysis was performed with the <i>HBB</i>-FR2 fragment to differentiate several alleles. We report a rapid and high-throughput technique that showed 100.0% concordance and low variability for each run. Our developed technique is one of the alternative techniques recommended for screening samples with both deletional and nondeletional globin gene mutations.
DOI: 10.6084/m9.figshare.12887880
title: CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: a systematic review and meta-analysis

description: Previously, many studies investigated the association between CYP19 rs2414096(G &gt; A) and susceptibility to develop PCOS. However, results had been inconsistent. Therefore, our systematic review and meta-analysis aimed to identify the association between CYP19 rs2414096 and PCOS risk. <i>Methods:</i> A systematic literature search was done from database PubMed, Google Scholar, Science Direct, and Cochrane Library up to July 15 2020 and statistical analysis was performed by RevMan5.3. <i>Results:</i> A total of seven studies comprised of 1414 PCOS cases and 1276 controls were included in the current meta-analysis. The pooled analysis showed that overall, there is a significant association between CYP19 rs2414096(G &gt; A) and risk of PCOS (OR = 0.74, 95% CI= 0.62–0.88, <i>p</i> = .0008). In dominant model, GG + AG vs GG and recessive genetic model AA vs AG + GG found a significant association (OR = 1.60,95% CI = 1.10–2.31, <i>p</i> = .01; OR = 0.65,95% CI = 0.45–0.93, <i>p</i> = .02) respectively which indicates that GG phenotype might be risk factor for PCOS development. In stratified subgroup analysis, there was significant association between CYP19 rs2414096 polymorphism and PCOS risk for non-Indian population only while no association was found with Indian population. <i>Conclusion:</i> Present meta-analysis studies indicate that CYP19 rs2414096 is associated with PCOS risk and important in pathogenesis of PCOS for many populations but for Indian population more studies are required as Indian population comprises of various subpopulations genetically isolated since long.
DOI: 10.6084/m9.figshare.12033711
title: Nature and sources of poisoning in patients admitted to a referral hospital in Gaborone, Botswana; findings and implications

description: Intentional poisoning is becoming an important public health concern particularly among young women globally. Consequently, there is a need to analyze this further within countries to establish pertinent policies to reduce current incidence rates. This includes sub-Saharan African countries where there has been a scarcity of information. Consequently, we sought to establish the nature and sources of poisoning in patients admitted to a leading hospital in Botswana to help develop pertinent future policies for Botswana and surrounding countries. Retrospectively reviewing the medical records of all patients admitted to Princess Marina Hospital (PMH), which is a leading tertiary hospital in the capital city of Botswana, due to acute poisoning over a six-year period. The records for 408 patients were reviewed. The majority of admissions (58%) were females, and the mean age of patients was 21(±14) years. Most poisoning cases (53%) were intentional. The 15–45 years age group was most likely to intentionally poison themselves compared to other age groups, with females four and half times more likely to intentionally poison themselves compared to males (AOR 4.53, 95% CI: 2.68–7.89, p The findings suggest in-depth and urgent investigations on intentional poisoning are needed among young women across countries including sub-Saharan African countries to inform future policies on prevention strategies. Further, strategies for poisoning prevention should target social and family relationship problems. We will be following this up in the future.
DOI: 10.6084/m9.figshare.12033711.v1
title: Nature and sources of poisoning in patients admitted to a referral hospital in Gaborone, Botswana; findings and implications

description: Intentional poisoning is becoming an important public health concern particularly among young women globally. Consequently, there is a need to analyze this further within countries to establish pertinent policies to reduce current incidence rates. This includes sub-Saharan African countries where there has been a scarcity of information. Consequently, we sought to establish the nature and sources of poisoning in patients admitted to a leading hospital in Botswana to help develop pertinent future policies for Botswana and surrounding countries. Retrospectively reviewing the medical records of all patients admitted to Princess Marina Hospital (PMH), which is a leading tertiary hospital in the capital city of Botswana, due to acute poisoning over a six-year period. The records for 408 patients were reviewed. The majority of admissions (58%) were females, and the mean age of patients was 21(±14) years. Most poisoning cases (53%) were intentional. The 15–45 years age group was most likely to intentionally poison themselves compared to other age groups, with females four and half times more likely to intentionally poison themselves compared to males (AOR 4.53, 95% CI: 2.68–7.89, p The findings suggest in-depth and urgent investigations on intentional poisoning are needed among young women across countries including sub-Saharan African countries to inform future policies on prevention strategies. Further, strategies for poisoning prevention should target social and family relationship problems. We will be following this up in the future.